Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
ALDX
ALDX
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
ALDX News
Surge in Options Trading Volume for ACMR and ALDX
3d ago
NASDAQ.COM
Healthcare Stocks with Strong Earnings Momentum Earn A+ EPS Revision Grades
Jan 16 2026
seekingalpha
FDA Prolongs Review Period for Aldeyra's Drug for Dry Eye Disease
Dec 16 2025
Benzinga
B. Riley Financial Shares Surge Approximately 25%; Check Out 20 Stocks Making Moves in Premarket Trading
Dec 16 2025
Benzinga
Aldeyra Shares Fall as FDA Postpones Review of Key Drug Marketing Application
Dec 16 2025
SeekingAlpha
FDA Prolongs Review Period for Aldeyra's Reproxalap NDA for Dry Eye Disease
Dec 16 2025
NASDAQ.COM
Aldeyra Extends NDA Review for Dry Eye Treatment to March 2026
Dec 16 2025
Businesswire
Aldeyra Extends PDUFA Date for Dry Eye Drug Application to March 2026
Dec 16 2025
Newsfilter
Biotech Stocks Await FDA Verdict in December 2025
Nov 27 2025
NASDAQ.COM
Aldeyra Therapeutics Expands RASP Platform to Address Central Nervous System Disorders and Shares Reproxalap Updates During Research & Development Webcast
Nov 13 2025
Newsfilter
Aldeyra Therapeutics to Attend the Jefferies Global Healthcare Conference in London
Nov 11 2025
Newsfilter
BTIG Affirms Buy Rating for Aldeyra Therapeutics, Keeps $9 Price Target Intact
Nov 10 2025
Benzinga
Aldeyra reorganizes pipeline and eliminates assets despite success in Phase II
Oct 29 2025
Yahoo Finance
Aldeyra's ADX-2191 Receives Orphan Drug Designation from EMA for Primary Vitreoretinal Lymphoma
Aug 28 2025
NASDAQ.COM
Aldeyra Therapeutics Granted Orphan Status by European Medicines Agency for ADX-2191 in Treating Primary Large B-Cell Lymphomas in Immune-Privileged Areas, Such as Primary Vitreoretinal Lymphoma
Aug 28 2025
Newsfilter
Key Stocks to Monitor: IOVA Rises Following Regulatory Approval, FDA Expedites Aldeyra's Medication
Aug 19 2025
NASDAQ.COM
Show More News
